Outpatient Surgery Magazine

Manager's Guide to Surgery's Ambulatory Anesthesia - July 2015

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://outpatientsurgery.uberflip.com/i/538156

Contents of this Issue

Navigation

Page 10 of 68

J U LY 2 0 1 5 O U T P A T I E N TS U R G E R Y. N E T 1 1 not been published and so it is apparently not peer-reviewed. It is a single-center study. It's not known whether the investigators or patients were blinded. No information is available on how the patients were selected. And Dr. Barrington also has a consulting relationship with Pacira. Another single-center 60-patient study awaiting publication pits 0.25% bupiva- caine against Exparel for subcostal TAP blocks for hysterectomy. The study showed that the Exparel patients used only half the opioids that the bupivacaine patients did — 3 Percocet per day instead of 6 — and also showed that they had lower minimum and maximum pain scores. But the controls received less than two-thirds of the medication that the study patients did. Average pain scores weren't reported. The study is small. And once again, it was designed by a Pacira consultant. Many surgeons became enthusiastic about Exparel, and many still are. By the end of 2014, Pacira had sold $189 million worth of Exparel, more than doubling the $76 million the drug had brought in the year before. Storm clouds But trouble was on the horizon. Other studies, particularly those whose authors had no relationship with Pacira, were critical. A review by 5 pharmacists published in Hospital Pharmacy in 2014 was high- ly skeptical of Exparel's value. The authors said Exparel's clinical trials had shown no statistical differences in pain scores. "The use of a new product is jus- tifiable when it fulfills an unmet need or the increased cost is offset by improved outcomes over current standard," says the study. "However, based on the available data, bupivacaine liposomal does not meet such a need." In 2015, a study in Pharmacotherapy testing Exparel against no drug in a mul- timodal setting in total knee patients found no statistical difference in pain scores between the group that received Exparel and the group that did not. The Exparel group did take fewer opioids than the control group.

Articles in this issue

Archives of this issue

view archives of Outpatient Surgery Magazine - Manager's Guide to Surgery's Ambulatory Anesthesia - July 2015